Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Samatasvir
Clinical data | |
---|---|
Routes of administration |
Oral |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG |
|
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C47H48N8O6S2 |
Molar mass | 885.07 g·mol−1 |
3D model (JSmol) | |
| |
|
Samatasvir (IDX-719) is an experimental drug for the treatment of hepatitis C. It was originally developed by Idenix, and development has been continued by Merck & Co. following their acquisition of Idenix. Samatasvir has shown good results in Phase II trials.
Samatasvir is a highly potent and selective inhibitor of the hepatitis C virus NS5A replication complex. While it showed promising results when administered as monotherapy, it is probable that samatasvir would be marketed as a combination product with other anti-hepatitis drugs to increase efficacy and reduce the chance of resistance developing, as with most other novel treatments for hepatitis C currently under development. Trials of samatasvir in combination with other antiviral drugs such as simeprevir are also underway.
See also
Hepatitis C |
|
||||||||
---|---|---|---|---|---|---|---|---|---|
Hepatitis D | |||||||||
Picornavirus | |||||||||
Anti-influenza agents | |||||||||
Multiple/general |
|
||||||||
|